Validation of the Erlangen Score Algorithm for Differential Dementia Diagnosis in Autopsy-Confirmed Subjects.


Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2019
Historique:
pubmed: 19 3 2019
medline: 28 8 2020
entrez: 19 3 2019
Statut: ppublish

Résumé

Despite decades of research on the optimization of the diagnosis of Alzheimer's disease (AD), its biomarker-based diagnosis is being hampered by the lack of comparability of raw biomarker data. In order to overcome this limitation, the Erlangen Score (ES), among other approaches, was set up as a diagnostic-relevant interpretation algorithm. To validate the ES algorithm in a cohort of neuropathologically confirmed cases with AD (n = 106) and non-AD dementia (n = 57). Cerebrospinal fluid (CSF) biomarker concentrations of Aβ1-42, T-tau, and P-tau181 were measured with commercially available single analyte ELISA kits. Based on these biomarkers, ES was calculated as previously reported. This algorithm proved to categorize AD in different degrees of likelihood, ranging from neurochemically "normal", "improbably having AD", "possibly having AD", to "probably having AD", with a diagnostic accuracy of 74% using the neuropathology as a reference. The ability of the ES to overcome the high variability of raw CSF biomarker data may provide a useful diagnostic tool for comparing neurochemical diagnoses between different labs or methods used.

Sections du résumé

BACKGROUND
Despite decades of research on the optimization of the diagnosis of Alzheimer's disease (AD), its biomarker-based diagnosis is being hampered by the lack of comparability of raw biomarker data. In order to overcome this limitation, the Erlangen Score (ES), among other approaches, was set up as a diagnostic-relevant interpretation algorithm.
OBJECTIVE
To validate the ES algorithm in a cohort of neuropathologically confirmed cases with AD (n = 106) and non-AD dementia (n = 57).
METHODS
Cerebrospinal fluid (CSF) biomarker concentrations of Aβ1-42, T-tau, and P-tau181 were measured with commercially available single analyte ELISA kits. Based on these biomarkers, ES was calculated as previously reported.
RESULTS
This algorithm proved to categorize AD in different degrees of likelihood, ranging from neurochemically "normal", "improbably having AD", "possibly having AD", to "probably having AD", with a diagnostic accuracy of 74% using the neuropathology as a reference.
CONCLUSION
The ability of the ES to overcome the high variability of raw CSF biomarker data may provide a useful diagnostic tool for comparing neurochemical diagnoses between different labs or methods used.

Identifiants

pubmed: 30883344
pii: JAD180563
doi: 10.3233/JAD-180563
pmc: PMC6484252
doi:

Substances chimiques

Amyloid beta-Peptides 0
Biomarkers 0
Peptide Fragments 0
amyloid beta-protein (1-42) 0
tau Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1151-1159

Références

Ann N Y Acad Sci. 2000;920:115-9
pubmed: 11193139
Neurology. 2002 Jun 25;58(12):1791-800
pubmed: 12084879
J Neuropathol Exp Neurol. 2002 Nov;61(11):935-46
pubmed: 12430710
Acta Neuropathol. 2006 Oct;112(4):389-404
pubmed: 16906426
J Neurochem. 2007 May;101(4):1053-9
pubmed: 17254013
Neurobiol Aging. 2008 Aug;29(8):1143-59
pubmed: 17428581
Acta Neuropathol. 2007 Jul;114(1):5-22
pubmed: 17579875
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
Neurochem Int. 2009 Sep;55(4):214-8
pubmed: 19524111
J Neural Transm (Vienna). 2009 Sep;116(9):1163-7
pubmed: 19653063
Arch Neurol. 2009 Oct;66(10):1240-6
pubmed: 19822779
Acta Neuropathol. 2010 Jan;119(1):1-4
pubmed: 19924424
Cerebrospinal Fluid Res. 2010 Jul 30;7:10
pubmed: 20673341
Int J Alzheimers Dis. 2010 Jul 15;2010:null
pubmed: 20798852
Acta Neuropathol. 2011 Jul;122(1):111-3
pubmed: 21644037
Alzheimers Dement. 2011 Jul;7(4):386-395.e6
pubmed: 21784349
Alzheimers Dement. 2012 Jan;8(1):65-73
pubmed: 22047631
Acta Neuropathol. 2012 Jan;123(1):1-11
pubmed: 22101365
Arch Gen Psychiatry. 2012 Jan;69(1):98-106
pubmed: 22213792
Neurology. 2012 Apr 3;78(14):1043-50
pubmed: 22377814
Biomark Med. 2012 Aug;6(4):419-30
pubmed: 22917144
Alzheimers Dement. 2013 Jul;9(4):406-13
pubmed: 23141384
J Alzheimers Dis. 2013;35(1):137-46
pubmed: 23364139
Lancet Neurol. 2014 Jun;13(6):614-29
pubmed: 24849862
PLoS One. 2014 Jun 24;9(6):e100784
pubmed: 24959687
J Alzheimers Dis. 2014;42(4):1239-50
pubmed: 25024328
J Alzheimers Dis. 2015;43(1):183-91
pubmed: 25079805
J Alzheimers Dis. 2015;45(3):813-22
pubmed: 25633670
Clin Chem. 2015 May;61(5):734-43
pubmed: 25869575
Front Neurol. 2015 Jun 17;6:138
pubmed: 26136723
Clin Chim Acta. 2015 Sep 20;449:9-15
pubmed: 26141614
Front Neurol. 2015 Jul 08;6:153
pubmed: 26217300
J Alzheimers Dis. 2015;48(2):433-41
pubmed: 26402007
Clin Chem Lab Med. 2016 Jul 1;54(7):1177-91
pubmed: 26495928
Alzheimers Dement. 2016 May;12(5):517-26
pubmed: 26555316
Front Neurol. 2015 Nov 27;6:247
pubmed: 26640457
Ann Clin Transl Neurol. 2016 Jan 01;3(3):154-65
pubmed: 27042676
Clin Chim Acta. 2017 Apr;467:27-33
pubmed: 27216941
J Alzheimers Dis. 2016 Aug 10;54(1):383-95
pubmed: 27567807
J Alzheimers Dis. 2016 Nov 19;55(2):813-822
pubmed: 27792012
Biomark Med. 2017 Feb;11(2):169-178
pubmed: 28111962
Alzheimers Res Ther. 2017 Jun 6;9(1):40
pubmed: 28587660
Neurology. 2017 Jul 4;89(1):88-100
pubmed: 28592453
Alzheimers Dement (Amst). 2017 May 18;8:111-126
pubmed: 28603768
J Alzheimers Dis. 2017;60(2):561-576
pubmed: 28869470
World J Biol Psychiatry. 2018 Jun;19(4):244-328
pubmed: 29076399
Clin Chem Lab Med. 2018 Nov 27;56(12):2058-2066
pubmed: 29949507

Auteurs

Charisse Somers (C)

Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.

Piotr Lewczuk (P)

Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen, and Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.
Department of Neurodegeneration Diagnostics, Medical University of Białystok, Białystok, Poland.

Anne Sieben (A)

Biobank, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.

Christine Van Broeckhoven (C)

Neurodegenerative Brain Diseases Group, Center for Molecular Neurology, VIB, Antwerp, Belgium.
Laboratory of Neurogenetics, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.

Peter Paul De Deyn (PP)

Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
Biobank, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium.

Johannes Kornhuber (J)

Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen, and Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.

Jean-Jacques Martin (JJ)

Biobank, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.

Maria Bjerke (M)

Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.

Sebastiaan Engelborghs (S)

Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH